sources, lack of political will, and the HIV-1 pandemic [4] . HIV-1-infected children may not develop the characteristic measles rash [5] and may have prolonged shedding of measles virus [6] . Children born to HIV-1-infected mothers may have lower levels of maternally acquired antibodies [7] , increasing the period of susceptibility before routine measles vaccination. Importantly, HIV-1-infected children may be less likely to respond to or maintain protective antibody levels after measles vaccination [5, 8] . Successful measles control in southern Africa suggests that the HIV-1 epidemic is not an insurmountable barrier to measles mortality reduction [9] . However, achieving the level of population immunity required for measles elimination may be difficult in regions of high HIV-1 prevalence.
Data on the immunogenicity of standard-titer measles vaccine among HIV-1-infected children derive largely from cross-sectional studies conducted in developed countries [5, 8] . Given the importance of achieving high levels of population immunity for measles elimination and the limited data on immune responses to measles vaccine in regions of high HIV-1 prevalence, we conducted a prospective study of the immunogenicity of standard-titer measles vaccine among HIV-1-infected and uninfected children in Lusaka, Zambia.
PATIENTS, MATERIALS, AND METHODS
Study setting. Zambia has one of the highest HIV-1 prevalence rates in the world, and measles was endemic until the supplementary immunization activity conducted in June 2003 [10] . At the time of the study, antiretroviral therapy was not available for treatment of HIV-1-infected children in Zambia outside the private sector. We conducted the study at Chawama Clinic, a public health care facility located in an urban township of Lusaka. The study was approved by the University of Zambia, the London School of Hygiene and Tropical Medicine, and the Johns Hopkins University Bloomberg School of Public Health.
Participants. Children between the ages of 2 and 8 months seeking routine childhood vaccination at Chawama Clinic from May 2000 to November 2002 were screened for eligibility. Those who were HIV seropositive by rapid immunoassay (Determine HIV-1/2; Abbott Laboratories) and a computer-generated random sample of HIV-seronegative children were eligible for enrollment. We obtained written informed consent from the parent or guardian before screening and enrollment.
Procedures. The Edmonston-Zagreb measles vaccine strain (Berna Biotec [formerly Swiss Serum and Vaccine Institute]) was administered subcutaneously in the upper arm by a trained health worker at ∼9 months of age. Vials of vaccine maintained under field conditions were returned to and potency was confirmed at the National At the time of vaccination and at each follow-up visit, a study clinical officer or nurse interviewed the mother or guardian about the child's medical history, examined the child for signs of illness, and recorded data on immunizations received (transcribed from the child's health record) as well as the child's length and weight on standard case-report forms (CRFs). We randomly assigned children to follow-up at 1 or 3 months after vaccination and asked mothers of all children to return at 15 and 27 months after vaccination and to seek care from the study team any time the child was ill. Children with signs and symptoms of measles were admitted to the hospital, and plasma measles virus-specific IgM antibodies were measured using an EIA (Wampole Laboratories).
Study clinical staff performed weekly home visits for 4 weeks after vaccination and noted reported signs and symptoms for each day of the preceding week on standard CRFs. We identified prospectively study children seeking care at Chawama Clinic or admitted to the main referral hospital and investigated potential cases of measles. In June 2003, Zambia vaccinated an estimated 97% of children aged 6 months to 14 years in a nationwide supplemental immunization activity [10] . We recorded the date of any revaccination of study children. Venous blood samples (3-5 mL) were obtained on the day of vaccination and at 1 or 3 and 15 and 27 months after vaccination. Automated white blood cell (WBC) count and hemoglobin measurements were made with the QBC Autoread Plus System (QBC Diagnostics). Differential WBC counts were determined manually. The percentages of CD4 + and CD8 + T lymphocytes in freshly isolated peripheral blood mononuclear cells were measured by flow cytometry (Becton Dickinson FACScan) using Cell Quest software (version 1.2) and directly conjugated monoclonal antibodies to CD3, CD4, and CD8 (Becton Dickinson). Plasma was separated, stored in aliquots at Ϫ70ЊC, and shipped on dry ice to the United States for further assays.
Antibodies to HIV-1 were measured again by EIA (Vironosticka HIV-1 Microelisa System; bioMérieux), and antibodypositive samples were assayed for HIV-1 RNA by reverse-transcriptase polymerase chain reaction (Amplicor HIV-1 Monitor version 1.5; Roche Molecular Systems).
A modified plaque reduction neutralization assay was used to measure measles antibodies [11] . Plasma samples were tested in parallel with the Second International World Health Organization (WHO) Serum Standard 66/202, with a titer of 1:8 corresponding to 8 mIU/mL. Paired samples of the pre-and 1-or 3-month postvaccination specimens were tested in the same assay. To assure comparability of results for different runs, data were analyzed only if the end-point titer measured for the WHO reference serum did not vary by 120% from the assigned titer of 1:5000. Logarithms of antibody levels were calculated, and geometric mean measles antibody concentrations and their 95% confidence intervals (CIs) were estimated. Samples with titers !1:8 were assigned a value of 2 mIU/mL for purposes of calculating geometric mean measles antibody concentrations.
Statistical analysis. Data were double-entered, checked, and validated using EpiInfo (version 6.04; Centers for Disease Control and Prevention [CDC]), and Stata (version 8.1; Stata) was used for analysis. We defined primary immune response within the first 6 months of vaccination in 2 different ways: seroconversion (a 4-fold rise in antibody titer, assuming an exponential decay in prevaccination antibody levels and a halflife of 6 weeks [12] ) or seropositivity (plaque reduction neutralization titer у1:120 [13] , which is equivalent to 120 mIU/ mL based on the performance of the Second International WHO Serum Standard 66/202). This level is considered protective against clinical measles [13] . Because primary responses Figure 1 . Study profile. "Reentered" refers to children vaccinated in the study who missed the prior follow-up visit but returned to reenter the study. *Children who did not return for the 15-month follow-up visit were revaccinated during the supplementary immunization activity (SIA) and returned for the 27-month follow-up visit; these children were not included in the analysis of antibody persistence at 27 months.
may vary according to the timing of the postvaccination blood sample [14] , we also examined responses at 1-2.9 and 3-5.9 months separately. We evaluated persistence of antibody (proportion seropositive and geometric mean measles antibody concentrations) at 15 and 27 months after vaccination among children who showed a primary immune response.
Children with confirmed or probable wild-type measles virus infection were excluded from analyses of antibody response to vaccination. Confirmed measles was defined as clinical measles [15] with measles virus-specific IgM antibodies, and probable measles was defined as a 4-fold rise in measles virus-specific IgG antibodies before vaccination. Children who had a 4-fold rise in antibody levels between 2 postvaccination time points but who did not report clinical symptoms were not excluded. Children revaccinated during supplementary immunization activities were excluded from analyses of antibody persistence, and their antibody levels after revaccination were analyzed separately.
When analyzing primary antibody responses, we classified children as HIV-1-infected if HIV-1 RNA was detected in any plasma sample obtained before or at the time of vaccination and compared antibody responses between HIV-1-infected children, HIV-seropositive but uninfected children, and HIVseronegative children. When analyzing antibody persistence, children were reclassified to reflect changes in HIV-1 infection status as HIV-1-infected at vaccination, HIV-1-uninfected at vaccination but infected at follow-up, or HIV-1-uninfected at follow-up. For some analyses, associations between risk factors and antibody levels at 15 and 27 months after measles vaccination were assumed to be similar. Therefore, these time points were combined, and random-effects models were used to adjust for children who returned at both time points.
Weight-for-height, weight-for-age, and height-for-age z scores were calculated with growth reference curves developed by the National Center for Health Statistics and the CDC [16] . Wasting was defined as a weight-for-height z score of 2 or more SDs below the reference population mean, underweight was defined as a weight-for-age z score of 2 or more SDs below the mean, and stunting was defined as a height-for-age z score of 2 or more SDs below the mean.
We used the x 2 test to compare proportions, logistic regression to compare measles seroresponses by HIV-1 infection status, and linear regression to identify predictors of (log-transformed) measles antibody concentrations. For multivariable analyses, variables were retained in the model if they were not on the causal pathway between HIV-1 infection and postvaccination antibody levels, if associations were observed at the level, and/or if they substantially altered estimates of P ! .05 the association of the primary exposure variables.
RESULTS
From May 2000 to November 2002, 4748 mothers were invited to participate, and 2190 children were screened; of these, 696 were eligible, and their mothers consented (figure 1). Fortyfour eligible children (6%) had probable or confirmed measles before age 9 months or within 17 days of vaccination, including 2 HIV-1-infected children with measles who died. HIV-1-infected children were more likely to acquire measles before 9 months of age (13% of 75 children) than uninfected children (5% of 621 children) ( ). At ∼9 months of age, 441 P p .008 children (63% of those enrolled) with no history of measles returned for measles vaccination, of whom 117 (27%) were HIV seronegative, 258 (58%) were HIV seropositive but uninfected, and 66 (15%) were HIV-1 infected. Figure 1 shows reasons for not receiving measles vaccination. HIV-seropositive children were more likely than HIV-seronegative children to have died (9% vs. 3%;
) before measles vaccination P p .006 and less likely to have withdrawn (6% vs. 13%;
). P p . In the analysis of the primary antibody response, we were able to include 359 (81%) of the vaccinated children (76% of 66 HIV-1-infected and 82% of 375 HIV-1-uninfected children). Ninety-eight were HIV seronegative (median age at vaccination, 9.1 [interquartile range {IQR}, 9.0-9.3] months), 211 were HIV seropositive but uninfected (median age, 9.1 [IQR, 9.0-9.3] months), and 50 were HIV-1 infected (median age, 9.0 [IQR, 9.0-9.1] months). Reasons for exclusion from this analysis are shown in figure 1 .
HIV-1-infected children were more likely than uninfected children to have a mother older than 30 years, be malnourished, have been hospitalized before vaccination, and have a low percentage (!25%) of CD4 + T lymphocytes at the time of measles vaccination (table 1). Distributions of prevaccination measles antibodies were similar in HIV-1-infected and uninfected children (table 1 and figure 2A ). Only 9% of the 359 children had measles antibody concentrations 150 mIU/mL at the time of vaccination, and the prevaccination geometric mean measles antibody concentration was 7 mIU/mL (95% CI, 5-7 mIU/mL) for HIV-seronegative children, 5 mIU/mL (95% CI, 4-6 mIU/ mL) for HIV-seropositive but uninfected children, and 7 mIU/ mL (95% CI, 4-10 mIU/mL) for HIV-1-infected children.
Primary antibody response. Of the 50 HIV-1-infected children, 88% became measles seropositive (у120 mIU/mL) within 6 months after vaccination, compared with 94% of 98 HIV-1-seronegative children and 94% of 211 HIV-1-seropositive but uninfected children ( ) (figure 2B and table 2) . Although P p .3 a slightly lower proportion of 37 HIV-1-infected children (84% [95% CI, 68%-94%]) were measles seropositive (у120 mIU/ mL) 1-2.9 months after vaccination, compared with 73 HIV-1-seronegative (92% [95% CI, 83%-97%]) and 147 HIV-1-seropositive but uninfected children (97% [95% CI, 92%-99%]), no differences were observed 3-5.9 months after vaccination. Only 2% of 257 children tested within 3 months of vaccination (range, 28-84 days) did not seroconvert to measles, none of whom was HIV-1 infected at the time of vaccination or subsequently. All 106 children tested 3-5.9 months after vaccination (including 4 who had been tested 1-2.9 months after vaccination) seroconverted to measles. In the 6 months after measles vaccination, geometric mean measles antibody concentrations did not differ substantially by HIV-1 infection status ( figure 2A and table 2) .
We adjusted for HIV-1 infection status to investigate the independent associations of other risk factors with primary antibody responses to measles vaccine. Children who were stunted at follow-up had lower antibody levels to measles virus than children who were not stunted (21% lower [95% CI, 1%-36%];
), but stunting was not associated with measles P p .04 seronegativity (!120 mIU/mL) (odds ratio [OR], 1.9 [95% CI, 0.8-4.5];
). Children who were wasted at follow-up were P p .16 more likely to be measles seronegative (OR, 4 [95% CI, 1.0-
17.3];
) and to have lower antibody levels to measles P p .05 virus (42% lower [95% CI, 68% lower to 7% higher]; P p ). Higher levels of maternal measles antibodies at vaccination .08 were associated with lower antibody levels 1-3 months after measles vaccination (22% lower for 10-fold higher levels of maternal antibodies [95% CI, 4%-36% lower];
; data P p .02 not shown), but this association was not evident 3-5.9 months after vaccination. The percentage of CD4 + T lymphocytes at vaccination was not significantly associated with seropositivity, but the number of children who were severely immunosuppressed (CD4 + T lymphocytes !15%) was small (table 2) . Persistence of measles neutralizing antibody. Twenty-nine (14%) of the HIV-1-seropositive but uninfected children at the time of measles vaccination later acquired HIV-1 infection, presumably via breast milk: nine within 6 months of vaccination, fifteen 6-14 months after vaccination, and five 15-27 months after vaccination. Persistence of measles neutralizing antibody was analyzed according to HIV-1 infection status at follow-up. Thirty-seven percent of the 335 children showing a primary response to measles vaccine (у120 mIU/mL) were revaccinated during the supplementary measles immunization activity and were excluded from the analysis of persistent an- Table 3 . Persistence of measles antibody by HIV-1 infection status and time from vaccination for children with a primary antibody response.
tibody. Persistence of measles antibody was assessed in 194 children ∼15 months after vaccination and in 89 children ∼27 months after vaccination. The median age and intervals between vaccination and follow-up visits were similar by HIV-1 infection status (data not shown).
The proportion of children who were measles seropositive 15 months after vaccination was significantly lower in children who were HIV-1 infected at the time of vaccination and in those who became HIV-1 infected after vaccination, compared with HIV-1-uninfected children ( ) (table 3) . Differ-P ! .001 ences between HIV-1-infected and uninfected children were more marked 27 months after vaccination ( ), but there P p .001 was little difference between children infected with HIV-1 before or after vaccination (table 3) . Geometric mean measles antibody concentrations at 27 months after vaccination were 75% lower (95% CI, 13%-93%; ) in the 7 children P p .03 infected with HIV-1 at the time of vaccination and 72% lower (95% CI, 20%-90%; ) in the 11 children who were P p .01 HIV-1 infected after vaccination, compared with 71 HIV-1-uninfected children.
Twenty-two children (13% of the HIV-seronegative, 8% of the HIV-seropositive but uninfected, and 17% of the HIV-1-infected children;
) had a 4-fold or greater increase in P p .34 measles antibody levels without reported clinical symptoms of measles between 6 and 15 months after vaccination, and 18 children (17% of the HIV-seronegative, 18% of the HIV-seropositive but uninfected, and 14% of the HIV-1-infected children;
) had a 4-fold or greater increase in levels between P p .98 15 and 27 months after vaccination.
Geometric mean measles antibody concentrations were 41% lower (95% CI, 19%-57%; ) in stunted children at P p .001 follow-up when the data at 15 and 27 months after vaccination were pooled and adjusted for HIV-1 infection (data not shown). Severely immunosuppressed (CD4 + T lymphocytes !15%) children at follow-up were more likely to be measles seronegative (!120 mIU/mL) 15 and 27 months after vaccination (OR, 4.9 [95% CI, 1.2-20.3];
) after adjusting for HIV-1 infec-P p .003 tion status.
Measles antibody levels after revaccination in the supplementary immunization activity. One hundred and twenty-eight children whose primary antibody response was known were revaccinated during the supplementary immunization activity; 34 before the 15-month visit and 94 between the 15-and 27-month visits. Within the latter group, 7 acquired HIV-1 infection after initial measles vaccination in infancy and were reclassified as HIV-1 infected.
All 34 children revaccinated before the 15-month visit had measles antibody concentrations у120 mIU/mL, and only 1 (an HIV-1-uninfected child) failed to achieve this level after revaccination (table 4) . Eleven (92%) of the 12 HIV-1-infected children revaccinated between the 15-and 27-month followup visits were measles seropositive after revaccination (table 4) , compared with 9 (50%) of 18 HIV-1-infected children who were not revaccinated (table 3) . HIV-1-infected children who were and were not revaccinated did not differ by immunological or nutritional status. The HIV-1-infected child who did not respond to revaccination was the only one who had not been measles seropositive after the primary dose. All 6 HIV-1-uninfected children who did not develop measles antibody concentrations у120 mIU/mL after primary vaccination became measles seropositive after revaccination. Antibody levels after revaccination in this time period were 55% lower (95% CI, 6%-78%; ) in the 12 HIV-1-infected children than in P p .03 the 82 uninfected children and 75% lower (95% CI, 41%-89%;
) in children who were severely immunocompromised P p .002 (CD4 + T lymphocytes !15%) than in those with у25% CD4 + T lymphocytes. We were not able to assess waning antibody levels after revaccination. Adverse events. Cough and rhinorrhea were the most commonly reported symptoms in the month after measles vaccination. The proportion of children reporting a symptom at least once did not differ by HIV-1 infection status ( ), P p .3 although HIV-1-infected children were more likely than uninfected children to report fever (55% vs. 41%;
) and P p .05 cough (70% vs. 57%;
). Seven children were admitted P p .06 to the hospital for suspected measles within 4-17 days (median, 8 days) of vaccination. Measles-like rash within 4 weeks of vaccination was reported during weekly surveillance for 3 HIV-1-infected children (1 hospitalized) and 6 uninfected children (2 hospitalized). The mortality of HIV-1-infected children was high (figure 1). Among HIV-1-infected infants who were vaccinated, 42% died during follow-up, compared with 3% of HIV-seropositive but uninfected and 1.7% of HIV-seronegative children. It is not known whether any HIV-1-infected child died as a complication of infection with measles vaccine virus.
DISCUSSION
HIV-1-infected Zambian children developed antibody levels considered to be protective after measles vaccination at ∼9 months of age, with comparable frequency to that achieved by HIV-1-uninfected children. This primary response is higher than has been reported previously in prospective studies of similar age groups in Thailand [17] , where only 57% of 14 HIV-1-infected children seroconverted, and in the Democratic Republic of Congo, where 65% of HIV-seropositive children had detectable measles antibody by EIA at 12 months of age and only 36% of 11 symptomatic children seroconverted, compared with 77% of 26 asymptomatic children [18] .
Our study was conducted when measles was endemic in Zambia. We attempted to exclude from the analysis children with confirmed or probable measles before vaccination. Some children with high prevaccination levels who did not meet our exclusion criteria, however, may have had subclinical or very mild wild-type measles virus infection, with partial protection conferred by maternally acquired antibodies. After vaccination, we excluded children with a history of clinical measles, but subclinical measles may have occurred, because some children showed a 4-fold or greater rise in antibody levels between 2 postvaccination time points.
Ours is the first study to show rapidly waning antibody levels to measles vaccine among HIV-1-infected African children, although only a small number of children survived to 2 and 3 years of age. Our results are consistent with data from the United States, where detectable measles virus-specific antibodies were found in 83% of 52 HIV-1-infected children studied within 1 year of vaccination but in only 57% of 14 children studied 11 year after vaccination ( ) [19] and the median P ! .01 time to loss of detectable antibody by EIA was 30 months [20] .
Measles supplementary immunization activities have been very effective in sub-Saharan Africa [3] , but there are few data on the immunogenicity of measles vaccine administered to older HIV-1-infected children during these campaigns. We found that HIV-1-infected children were more likely to have protective antibody levels after revaccination than children who had not received a supplemental dose. The present study was not designed to assess persistence of antibody after revaccination. The few, small studies of revaccination of HIV-1-infected children have shown variable but generally poor responses [5] .
The WHO now recommends a second opportunity for measles vaccination for all children, either through repeated campaigns or a routine second dose [21] . Our data suggest that this will be especially important in regions of high HIV-1 prevalence because of waning immunity among HIV-1-infected children. Sufficient resources must be invested in maintaining high levels of population immunity against measles in regions of high HIV-1 prevalence as well as in strategies to prevent HIV-1 infection and to treat HIV-1-infected persons.
